# Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)

> **NCT02773732** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Florida** · enrollment: 11 (actual)

## Conditions studied

- Leukemia
- Acute Myelogenous Leukemia
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Ciprofloxacin 750 MG
- **DRUG:** Etoposide
- **DRUG:** Ciprofloxacin 1000 MG
- **DRUG:** Ciprofloxacin 500 mg

## Key facts

- **NCT ID:** NCT02773732
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-16
- **Primary completion:** 2021-09-07
- **Final completion:** 2021-11-15
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** slow enrollment
- **Last updated:** 2022-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02773732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02773732, "Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02773732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*